MedTrace Logo

LEO 32731 - A Phase I Study in Healthy Subjects

NCT02514694 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2017-05-03

No results posted yet for this study

Summary

LEO 32731 ("Study Drug") is an investigational drug which is being developed by LEO Pharma A/S ("the Sponsor") for treatment of psoriasis. The aim (s) of this Study are to determine:

* The safety and tolerability of the Study Drug and any side effects that might be associated with it
* The Study will also measure how much of the Study Drug that gets into the blood and how long time it takes for the body to remove it.

Conditions

  • Psoriasis Vulgaris

Interventions

DRUG

LEO32731

OTHER

Placebo

Sponsors & Collaborators

  • LEO Pharma

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02514694 on ClinicalTrials.gov